For HR− patients, 21/29 patients (72.4%) were triple-negative breast cancer (TNBC) in the sub-group of high Ki-67 level, and 16/19 (84.2%) were TNBC in the sub-group of low Ki-67 level. This evidence concerns the gene MKI67 and triple-negative breast carcinoma.